Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients

© 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the populat...

Full description

Saved in:
Bibliographic Details
Main Authors: Kanokrat Rungtivasuwan, Anchalee Avihingsanon, Narukjaporn Thammajaruk, Siwaporn Mitruk, David M. Burger, Kiat Ruxrungtham, Chonlaphat Sukasem, Baralee Punyawudho
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56682
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-56682
record_format dspace
spelling th-cmuir.6653943832-566822018-09-05T03:51:29Z Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics © 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A>G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients. 2018-09-05T03:28:53Z 2018-09-05T03:28:53Z 2017-11-01 Journal 17448042 14622416 2-s2.0-85034419484 10.2217/pgs-2017-0128 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56682
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics
spellingShingle Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics
Kanokrat Rungtivasuwan
Anchalee Avihingsanon
Narukjaporn Thammajaruk
Siwaporn Mitruk
David M. Burger
Kiat Ruxrungtham
Chonlaphat Sukasem
Baralee Punyawudho
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
description © 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A>G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients.
format Journal
author Kanokrat Rungtivasuwan
Anchalee Avihingsanon
Narukjaporn Thammajaruk
Siwaporn Mitruk
David M. Burger
Kiat Ruxrungtham
Chonlaphat Sukasem
Baralee Punyawudho
author_facet Kanokrat Rungtivasuwan
Anchalee Avihingsanon
Narukjaporn Thammajaruk
Siwaporn Mitruk
David M. Burger
Kiat Ruxrungtham
Chonlaphat Sukasem
Baralee Punyawudho
author_sort Kanokrat Rungtivasuwan
title Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
title_short Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
title_full Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
title_fullStr Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
title_full_unstemmed Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
title_sort pharmacogenetics-based population pharmacokinetic analysis of tenofovir in thai hiv-infected patients
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56682
_version_ 1681424737675247616